Fosfomycin Sodium for Injection

Fosfomycin has antibacterial effects on Gram-positive cocci such as Staphylococcus aureus and Staphylococcus epidermidis. It also has strong antibacterial activity against Gram-negative bacteria such as Escherichia coli, Serratia, Shigella, Yersinia, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter aerogenes, Vibrio and Aeromonas. Fosfomycin can inhibit the early synthesis of bacterial cell walls. Its molecular structure is similar to phosphoenolpyruvate, so it can compete with bacteria for the same transferase, inhibiting bacterial cell wall synthesis and leading to bacterial death.

The main ingredient of this product is fosfomycin sodium. Its chemical name is (—)-(1R,2S)-1,2-epoxypropylphosphonic acid disodium salt. Molecular formula: C3H5Na2O4P Molecular weight: 182.02

This product is white crystalline powder.

This product is used for respiratory tract infections, urinary tract infections, skin and soft tissue infections caused by sensitive bacteria. It can also be used in combination with other antibiotics to treat severe infections caused by sensitive bacteria such as sepsis, peritonitis, osteomyelitis, etc.

Intravenous drip. Dissolve in sterile water for injection, then dilute in 250-500ml of 5% glucose injection or sodium chloride injection and drip intravenously. 1 Adults: 4-12g per day, increase to 16g per day for severe infection. Drip in 2-3 times. 2 Children: 0.1-0.3g/kg per day, drip in 2-3 times.

1. Mainly mild gastrointestinal reactions, such as nausea, poor appetite, upper abdominal discomfort, loose stools or mild diarrhea, which generally do not affect continued medication. 2. Occasionally, skin rash, eosinophilia, transient decrease in peripheral blood red blood cells, platelets, leukocyte decrease, transient increase in serum aminotransferase, dizziness, headache and other reactions may occur. 3. Injection site phlebitis. 4. Shock may occur in very few patients.

Patients who are allergic to this product are prohibited from using it.

Precautions for children: There is still a lack of data on the safety of this product for children. It should not be used in children under 5 years old. Children over 5 years old should use it with caution and in reduced dosage. Precautions for pregnancy and lactation: This product can pass through the placenta and quickly enter the fetal circulation. However, there is no sufficient and strict control observation on the effect on the fetus. Therefore, it should be prohibited for pregnant women. This product can also be excreted through breast milk. Therefore, breastfeeding women should avoid using it. If the drug must be used, breastfeeding should be suspended. Precautions for the elderly: Since this product is mainly excreted from the kidneys, the liver and kidney functions of the elderly are often physiologically reduced, so the elderly should use it with caution and reduce the dosage according to the patient's condition.

1. It has a synergistic effect with beta-lactam antibiotics against Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa. 2. It has a synergistic effect when used in combination with aminoglycoside antibiotics. 3. The in vitro antibacterial activity of this product is easily weakened by the interference of glucose or (and) phosphate in the culture medium. Adding a small amount of glucose-6-phosphate can enhance the effect of this product.

Keep tightly closed in a cool, dry place.

Calculated as C3H7O4P 1.0g (1 million units)

24 months

Harbin Pharmaceutical Group Sanjing Mingshui Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-30

• Address:

  Sanjing Pharmaceutical Industrial Park, Mingshui County, Suihua City, Heilongjiang Province

• Tax NO.:

  91231225726919956Y

• Registered Funds:

  40 million yuan

• Email:

  Log in to view